Neal Shore and Oliver Sartor discuss the role of both alpha and beta radiopharmaceuticals that are on the horizon for treatment of bone metastases in prostate cancer.  Dr. Sartor reviews the compelling data for the use radium-223 with respect to the improvement seen in overall survival along with additional alpha targeted agents that are on the horizon. He also discusses the role of the beta agents including a review of the enrolling VISION trial with PSMA-617 in men who have failed abiraterone, enzalutamide or taxanes. Drs. Shore and Sartor close the discussion with a review of the ERA-223 data and the implications for combining treatments upfront with radium-223 or utilizing a sequencing approach.

Biographies:

A. Oliver Sartor, MD, is currently the Assistant Dean for Oncology at Tulane University School of Medicine, Medical Director of the Tulane Cancer Center and the Laborde Professor for Cancer Research, with appointments in both the Medicine and Urology Departments.

Neal Shore, MD, FACS Board Certified Urologist, Medical Director of the Carolina Urologic Research Center, Atlantic Urology Clinics